| Freehill Mining Limited (FHS) ORDINARY FULLY PAID |
Materials |
$8 |
Samples grading up to 4.0% Cu from El Dorado exploration
|
14 Aug 2025 9:39AM |
$0.004 |
$0.002 |
fallen by
50%
|
|
FHS - Price-sensitive ASX Announcement
Full Release
Key Points
- Freehill Mining Limited (ASX: FHS) conducted exploration at the El Dorado project in Chile.
- Rock chip samples returned grades up to 4.0% copper (Cu).
- Sampling focused on outcrops with visible copper minerals such as malachite and chrysocolla.
- Several new copper targets identified in the southern part of the project area.
- Results confirm high-grade copper mineralisation at surface.
- Company intends to continue systematic exploration, including geophysics and drilling.
- The El Dorado project is a key focus for expanding copper resources.
- These findings align with Freehill Mining's strategy to advance copper exploration in Chile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Red Mountain Mining Limited (RMX) ORDINARY FULLY PAID |
Materials |
$13 |
Prospectus (Loyalty Options Offer)
|
14 Aug 2025 9:39AM |
$0.008 |
$0.012 |
risen by
50%
|
|
RMX - Price-sensitive ASX Announcement
Full Release
Key Points
- Red Mountain Mining Limited (RMX) is offering a pro-rata non-renounceable loyalty options offer to eligible shareholders.
- Eligible shareholders as of 11 June 2021 can receive one Loyalty Option for every three ordinary shares held.
- The Loyalty Options are exercisable at $0.021 on or before 30 June 2023.
- The offer is intended to reward and incentivise long-term shareholders.
- The prospectus provides detailed terms, eligibility criteria, and the timetable for the offer.
- Funds raised from the exercise of options will be used for exploration and working capital.
- The document outlines risks related to the offer and RMX’s business operations.
- RMX’s mineral projects, exploration activities, and future plans are described.
- Directors’ interests, expert consents, and rights of securities are included.
- Participation in the offer involves investment risks consistent with mineral exploration companies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kinetiko Energy Limited (KKO) ORDINARY FULLY PAID |
Energy |
$54 |
Trading Halt
|
14 Aug 2025 9:39AM |
$0.099 |
$0.035 |
fallen by
64.65%
|
|
KKO - Price-sensitive ASX Announcement
Full Release
Key Points
- Kinetiko Energy Limited requested a trading halt on its securities from 5 June 2023.
- The trading halt is pending an announcement regarding a capital raising.
- The halt will remain until 7 June 2023 or until a relevant announcement is released, whichever comes first.
- The request was made pursuant to ASX Listing Rule 17.1.
- The company is not aware of any reason why the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WA1 Resources Ltd (WA1) ORDINARY FULLY PAID |
Materials |
$854 |
Trading Halt
|
14 Aug 2025 9:38AM |
$19.340 |
$11.490 |
fallen by
40.59%
|
|
WA1 - Price-sensitive ASX Announcement
Full Release
Key Points
- WA1 Resources Ltd requested a trading halt effective 5 June 2024.
- The trading halt is related to a pending capital raising announcement.
- The halt will remain until the announcement is made or normal trading resumes on 7 June 2024.
- The request was formally submitted to the ASX.
- The halt is to ensure the orderly release of price-sensitive information.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$20,173 |
CEO Interview FY25 Results
|
14 Aug 2025 9:37AM |
$297.150 |
$193.100 |
fallen by
35.02%
|
|
PME - Price-sensitive ASX Announcement
Full Release
Key Points
- Pro Medicus had a record year with strong financial growth and secured seven new contracts valued at a minimum of AUD $520M.
- The majority of new contract revenue is expected to be realized in FY26, with forward contracted revenue for the next 5 years at AUD $948M.
- Cloud solutions are preferred by Pro Medicus clients for scalability, security, and cost-effectiveness, with a fully cloud-based offering unlike competitors' hybrid solutions.
- Pro Medicus is advancing in AI with collaborations and licensing agreements, notably for breast cancer detection and plaque algorithms.
- The company holds 10% of the North American market share, with significant growth potential due to its cloud-based platform and efficient implementation process.
- Cardiology is a critical component of contracts, enhancing the total value for clients, with plans to integrate other medical 'ologies'.
- The company's EBIT margins increased to 74%, with further growth potential from new contracts.
- Pro Medicus focuses on premium pricing, providing high ROI both financially and clinically.
- The company has over $210 million in cash reserves for growth investment, dividends, and potential acquisitions.
- Pro Medicus has a strong renewal record, with key contracts extended at higher fees.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$20,173 |
CEO Interview FY25 Results
|
14 Aug 2025 9:37AM |
$297.150 |
$193.100 |
fallen by
35.02%
|
|
PME - Price-sensitive ASX Announcement
Full Release
Key Points
- Pro Medicus Limited had its strongest financial year in FY25.
- Secured seven new contracts totaling AUD $520 million.
- Cloud solutions are a strategic focus for scalability and security.
- Unique 100% cloud-based offering distinguishes Pro Medicus from competitors.
- AI advancements include collaborations with UCSF and NYU Langone.
- Cardiology and pathology integrations in Visage 7 platform.
- Maintained a 100% renewal rate for existing contracts.
- Forward contracted revenue expected to reach AUD $948 million in five years.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Staude Capital Global Value Fund Limited (GVF) ORDINARY FULLY PAID |
Financials |
$276 |
Investment Update and NTA Value as at 31 July 2025
|
14 Aug 2025 9:37AM |
$1.425 |
$1.360 |
fallen by
4.56%
|
|
| Carnegie Clean Energy Limited (CCE) ORDINARY FULLY PAID |
Utilities |
$85 |
SPP Chairman's Letter and Flyer
|
14 Aug 2025 9:36AM |
$0.058 |
$0.205 |
risen by
253.45%
|
|
| Lithium Universe Limited (LU7) ORDINARY FULLY PAID |
Materials |
$10 |
Application for quotation of securities - LU7
|
14 Aug 2025 9:36AM |
$0.008 |
$0.006 |
fallen by
25%
|
|
| FSA Group Limited (FSA) ORDINARY FULLY PAID |
Financials |
$162 |
Dividend/Distribution - FSA
|
14 Aug 2025 9:36AM |
$0.955 |
$1.295 |
risen by
35.60%
|
|
| FSA Group Limited (FSA) ORDINARY FULLY PAID |
Financials |
$162 |
Appendix 4E and Annual Report 2025
|
14 Aug 2025 9:36AM |
$0.955 |
$1.295 |
risen by
35.60%
|
|
FSA - Price-sensitive ASX Announcement
Full Release
Key Points
- FSA Group Limited released its Appendix 4E and Annual Report for the year ended 31 March 2025.
- Profit after tax decreased compared to the previous year.
- The report covers consolidated financial statements, director's report, and corporate governance statement.
- Segment performance, earnings per share, and dividends are detailed.
- Cash flow and financial position as of 31 March 2025 are reviewed.
- Strategic focus areas and principal risks affecting the group are discussed.
- Directors' declaration of compliance with Australian Accounting Standards is included.
- An independent audit report is provided.
- The document outlines significant changes in operations and future outlook.
- Events occurring after 31 March 2025 are disclosed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Red Mountain Mining Limited (RMX) ORDINARY FULLY PAID |
Materials |
$13 |
Target Market Determination
|
14 Aug 2025 9:35AM |
$0.008 |
$0.012 |
risen by
50%
|
|
| WAM Capital Limited (WAM) ORDINARY FULLY PAID |
Financials |
$1,798 |
Corporate Governance Statement
|
14 Aug 2025 9:35AM |
$1.705 |
$1.580 |
fallen by
7.33%
|
|
| Rincon Resources Limited (RCR) ORDINARY FULLY PAID |
Materials |
$7 |
Notification regarding unquoted securities - RCR
|
14 Aug 2025 9:34AM |
$0.014 |
$0.014 |
fallen by
0%
|
|
| Legacy Minerals Holdings Limited (LGM) ORDINARY FULLY PAID |
Materials |
$22 |
Thomson Drilling Assays and Further Drilling Planned
|
14 Aug 2025 9:34AM |
$0.155 |
$0.110 |
fallen by
29.03%
|
|
| Adriatic Metals Plc (ADT) ORDINARY FULLY PAID |
Materials |
- |
Results of DPM Special Meeting
|
14 Aug 2025 9:34AM |
$6.050 |
$6.220 |
risen by
2.81%
|
|
| KKR Credit Income Fund (KKC) ORDINARY UNITS FULLY PAID |
Financials |
$669 |
Net Tangible Asset Backing
|
14 Aug 2025 9:32AM |
$2.370 |
$2.075 |
fallen by
12.45%
|
|
| Red Mountain Mining Limited (RMX) ORDINARY FULLY PAID |
Materials |
$13 |
Proposed issue of securities - RMX
|
14 Aug 2025 9:32AM |
$0.008 |
$0.012 |
risen by
50%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$124 |
Presentation to the Third Annual Dengue Endgame Summit
|
14 Aug 2025 9:32AM |
$0.195 |
$0.420 |
risen by
115.38%
|
|
| Way 2 Vat Ltd (W2V) ORDINARY FULLY PAID |
Information Technology |
$15 |
Notice of Annual General Meeting/Proxy Form
|
14 Aug 2025 9:31AM |
$0.007 |
$0.059 |
risen by
742.86%
|
|
| Trigg Minerals Limited (TMG) ORDINARY FULLY PAID |
Materials |
- |
High-Grade Channel Samples at Antimony Canyon Project - Utah
|
14 Aug 2025 9:31AM |
$0.099 |
$0.120 |
risen by
21.21%
|
|
TMG - Price-sensitive ASX Announcement
Full Release
Key Points
- Trigg Minerals Limited (TMG) announced high-grade channel sampling results from its Antimony Canyon Project in Utah, USA.
- The company identified significant antimony mineralisation at the project, including samples with up to 13.5% Sb (antimony) and notable gold values up to 1.03 g/t Au.
- Channel samples were taken from historic mine workings and surface exposures, confirming widespread antimony and gold mineralisation across multiple structures.
- The sampling program enhances the geological understanding of the project area and supports the potential for a significant antimony-gold system.
- TMG plans to follow up with additional exploration, including drilling, mapping, and geochemical surveys, to further define mineralisation and test priority targets.
- The Antimony Canyon Project is strategically located in Utah, an area known for critical mineral deposits and historic antimony production.
- The announcement aligns with TMG’s strategy to advance projects with exposure to critical minerals essential for global supply chains.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| RocketDNA Ltd (RKT) ORDINARY FULLY PAID |
Information Technology |
$26 |
Director Interest Notices
|
14 Aug 2025 9:30AM |
$0.012 |
$0.021 |
risen by
75%
|
|
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$20,173 |
Dividend/Distribution - PME
|
14 Aug 2025 9:29AM |
$297.150 |
$193.100 |
fallen by
35.02%
|
|
| Aurum Resource Limited (AUE) ORDINARY FULLY PAID |
Materials |
$208 |
Change of Director's Interest Notice (X4)
|
14 Aug 2025 9:29AM |
$0.515 |
$0.505 |
fallen by
1.94%
|
|
| FSA Group Limited (FSA) ORDINARY FULLY PAID |
Financials |
$162 |
Appendix 4G 2025
|
14 Aug 2025 9:27AM |
$0.955 |
$1.295 |
risen by
35.60%
|
|
Call 1300 880 160
Start a chat
Schedule a call
